Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs. In both, vedolizumab was used continuously without side effects, and long-term remission has been durable. Duodenal ulcers associated with EGIDs are increasing. Vedolizumab has potential as a treatment for even upper gastrointestinal lesions in refractory EGIDs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12328-025-02096-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis.
Clin J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 3308777, Japan.
Eosinophilic gastrointestinal disorders (EGIDs) are treated with corticosteroids and food allergen elimination. However, treatment for refractory cases is not standardized. We demonstrate the efficacy of vedolizumab, an anti-α4β7 integrin agent, in 2 children with duodenal ulcers developed by non-eosinophilic esophagitis EGIDs.
View Article and Find Full Text PDFComplex Cardiovascular Management in an 80-Year-Old Female With Gastrointestinal Bleeds and Klatskin Tumor: A Case of ST-Elevation Myocardial Infarction (MI) Management Complicated by Severe Anemia and Post-MI Ventricular Septal Defect Development.
Cureus
December 2024
Interventional Cardiology, Lee Health, Fort Myers, USA.
Managing acute coronary syndrome (ACS) in patients with a recent history of gastrointestinal bleeding presents a unique and challenging clinical dilemma, necessitating a careful balance between minimizing ischemic risk and avoiding potentially life-threatening rebleeding. Standard treatment for ACS typically involves dual antiplatelet therapy (DAPT) to prevent recurrent thrombotic events. However, in patients with recent gastrointestinal hemorrhage or significant anemia, these therapies may substantially increase the risk of life-threatening bleeding, complicating the decision-making process and often leading to conservative management strategies.
View Article and Find Full Text PDFRefractory duodenal ulcer caused by portal stent graft exposure.
Clin Endosc
January 2025
Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Clinical Epidemiology, Etiology, and Outcomes of Upper Gastrointestinal Bleeding at a Tertiary Center in Bahrain: A Retrospective Study.
Cureus
January 2025
Department of Gastroenterology and Hepatology, Salmaniya Medical Complex, Manama, BHR.
Background Upper gastrointestinal bleeding (UGIB) is one of the most common major medical emergencies. This study sought to determine the epidemiology, clinical characteristics, and outcomes of UGIB in the largest major tertiary care center in Bahrain, compared to regional and international cohorts. Methods We conducted a retrospective cohort study of all patients diagnosed with UGIB between April 2021 and April 2022 in Salmaniya Medical Complex, Bahrain's largest tertiary-level public hospital.
View Article and Find Full Text PDFIschemic cholangiopathy secondary to endoscopic treatment of bleeding duodenal ulcer.
Rev Esp Enferm Dig
January 2025
Cirugía General y del Aparato Digestivo, Hospital Universitario 12 de Octubre.
Case report of a patient with a duodenal ulcer, initially treated with sclerosing agents, as is common practice for most bleeding ulcers. However, the evolution following this treatment is unusual. The patient developed secondary ischemic cholangitis, leading to extensive aerobilia and secondary portal pneumatosis, accompanied by inflammatory changes in the head of the pancreas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!